Table 2 The clinicopathological features of patients with DLBCL
From: MiR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1
| Characteristic | Total number of patients | Expression of miR-214 | P value | |
|---|---|---|---|---|
| 15 | High (N = 7) | aLow (N = 8) | ||
| Age (years) | 0.447 | |||
| ≥ 55 | 8 (53.33%) | 3 | 5 | |
| < 55 | 7 (46.67%) | 4 | 3 | |
| Gender | 0.833 | |||
| Male | 9 (60.00%) | 4 | 5 | |
| Female | 6 (40.00%) | 3 | 3 | |
| Tumor size (cm) | 0.020 | |||
| ≥ 3 | 9 (60.00%) | 2 | 7 | |
| < 3 | 6 (40.00%) | 5 | 1 | |
| Clinical stage | 0.036 | |||
| I - II | 5 (33.33%) | 4 | 1 | |
| III - IV | 10 (66.67%) | 2 | 7 | |
| bLDH | 0.782 | |||
| High (≥ 300) | 8 (53.33%) | 4 | 4 | |
| Low (< 300) | 7 (46.67%) | 3 | 4 | |
| cIPI | 0.013 | |||
| Low (0–2) | 4 (26.67%) | 4 | 0 | |
| High (≥ 3) | 11 (73.33%) | 3 | 8 | |